http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102872068-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ac31afbea1cbbb03498644721ffb4a62
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00
filingDate 2012-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a921d1cb48faa70d57bc39fbf040d61a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_719b0310d7da41ad2fcd37b6576318a2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3ca1f1bd52ea522193c62342978e43c3
publicationDate 2013-01-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-102872068-A
titleOfInvention Application of Houttuynoid E in the treatment of colorectal cancer
abstract The invention discloses the application of HouttuynoidE in the preparation of medicines for treating human colorectal cancer, and belongs to the technical field of new medicine applications. The present invention finds through MTT anti-tumor activity evaluation in vitro that HouttuynoidE also has significant inhibitory effect on the growth of human colorectal cancer cell lines LOVE1, LoVo, SW620 and SW480. Therefore, HouttuynoidE can be used to prepare anti-colorectal cancer drugs, and has good development and application prospects. The use of the HouttuynoidE involved in the present invention in the preparation of medicines for treating human colorectal cancer is disclosed for the first time, because the skeleton type is a brand-new skeleton type, and its inhibitory activity against human colorectal cancer cells is unexpectedly strong.
priorityDate 2012-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467785216

Total number of triples: 15.